Clinical trials

Brain inflammation
#Amyotrophic lateral sclerosis (ALS) #Axoltis Pharma #Blood brain barrier #Clinical trials #Neuroscience #Regulatory

Drug candidate for ALS patients authorised for Phase II trial

Axoltis Pharma has received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for Amyotrophic Lateral Sclerosis (ALS).   This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of the blood brain… Read More

#News #Regulatory

HIV cell
#Biotechnology #Clinical trials #HIV #Immunology / Virology & Vaccines #Naobios #Sumagen

Naobios and Sumagen partner to develop HIV vaccine 

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials.  At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV. Developing an… Read More

#Business & Investment #News

Weighing scale
#Clinical trials #Obesity #Patient centricity

Overcoming challenges in obesity-related clinical trials 

Deirdre Albertson, Vice President, Project Management, Cardiovascular/Metabolic Division, ICON, Jack L Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON and Simon Bruce, MD VP, Internal Medicine, Drug Development Solutions, ICON, assess the clinical trials landscape for obesity and ask why patient centricity is key to overcoming common… Read More

#Exclusive Content

Heart
#Clinical trials #Corteria Pharmaceuticals #Heart failure #Hormone therapy #Worsening Heart Failure

Phase I study to evaluate treatment of worsening heart failure 

Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF).  COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart,… Read More

#News

#Breast cancer #Clinical trials #Covid-19 #DDW Highlights podcast #FDA #lcohol Use Disorder #Mergers and acquisitions #Psychedelics

New DDW Highlights podcast: 2 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In another busy week for drug discovery and development, we have seen the FDA… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trials #Neuroscience #NeuroSense

NeuroSense reports positive results from its ALS trial 

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).   The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the… Read More

#News

Clinical trial
#Clinical trials #Dermatology #Johnson & Johnson #Plaque Psoriasis

J&J presents successful data from plaque psoriasis trial  

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor.  IL-23 plays a critical role in pathogenic T-cell activation… Read More

#News

Handshake jigsaw puzzle
#AstraZeneca #Clinical trials #MSD #Prostate cancer #Scottish Medicines Consortium

Therapy for advanced prostate cancer approved in Scotland 

The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the most common… Read More

#Cancer Research #News #Regulatory

Human liver
#Biosciences #Clinical trials #Drug discovery #Liver disease #Ochre Bio

Podcast: Unlock the potential of complex human liver data

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Quin Wills, Co-founder… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Data security #Decentralised clinical trials

Decentralised identities: Blockchain based informed consent

Industry experts explain how blockchain can fundamentally enhance clinical trials. Obtaining consent from patients or healthy volunteers is a fundamental requirement for enrolling participants on to clinical trials. Methods for obtaining consent use paper-based Informed Consent Forms (ICFs) must be signed on site by the participant in the presence of… Read More

#Exclusive Content

Neuroscience Parkinson's disease
#Clinical trials #Gain Therapeutics #Neuroscience #Parkinson's

Restored motor function in mouse models of Parkinson’s disease  

Gain Therapeutics has announced preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration.   The data were accepted as a late-breaker abstract and was presented at the 20th Annual WORLDSymposium.  “We… Read More

#News

Intestine
#Clinical trials #Gastrointestinal #Orexa #Postoperative ileus

First patient dosed in Phase II trial in post-operative patients 

Orexa has dosed the first patients in a Phase II clinical trial in the prevention of postoperative ileus. The trial investigates whether patients who undergo major abdominal surgery will develop less gastrointestinal disturbances and will recover more quickly.  The Dutch life sciences company is developing a new… Read More

#News

Stem cells
#CDMO #Clinical trials #Drug delivery #EXO Biologics #Exosomes #ExoXpert #Mesenchymal stem cells

CDMO launched to service increasing demand for exosomes 

EXO Biologics has launched ExoXpert, a contract development and manufacturing organisation (CDMO) specialising in exosomes which offers a mesenchymal stem cells (MSC)-based exosome manufacturing platform used in European clinical trials.  During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing… Read More

#News

#Bispecific Antibodies #Cancer treatment #Checkpoint inhibitor therapies #Clinical trials #Solid tumours

Phase I trial for first-in-class bispecific antibody for cancer

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.  The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201.   The study is a European multicentre and… Read More

#Cancer Research #News

#Biopharmaceuticals #Clinical trials #Diabetes #Diabetic macular oedema #Eye health #Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy  

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).  Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR)… Read More

#News